NASDAQ: ICCMIcecure Medical Ltd Stock
$5.40-1.00 (-15.63%)
Updated Jun 18, 2026
ICCM Price
$5.40
Fair Value Price
N/A
Market Cap
$14.61M
52 Week Low
$2.12
52 Week High
$42.00
P/E
-0.75x
P/B
1.72x
P/S
6.21x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.57M
Earnings
-$15.74M
Gross Margin
36.5%
Operating Margin
-439.94%
Profit Margin
-441.6%
Debt to Equity
0.57
Operating Cash Flow
-$15M
Beta
0.69
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ICCM Overview
IceCure Medical Ltd. develops medical devices to cryoablate (freeze) tumors in the human body. It offers the ProSense system, a cryoablation solution for the treatment of breast tumors. Icecure Medical supports investigator-initiated studies at various academic institutions. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ICCM's potential to beat the market
- ICCM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
ICCM
RankedUnranked of 93
RankedUnranked of 93
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.71 | A | |
| $38.68 | A | |
| $26.62 | A |
Be the first to know about important ICCM news, forecast changes, insider trades & much more!
ICCM News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ICCM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ICCM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ICCM is good value based on its book value relative to its share price (1.72x), compared to the US Medical Devices industry average (2.95x)
P/B vs Industry Valuation
ICCM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ICCM due diligence checks available for Premium users.
Valuation
ICCM fair value
Fair Value of ICCM stock based on Discounted Cash Flow (DCF)
Price
$5.40
Fair Value
-$0.44
Undervalued by
1,323.94%
ICCM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ICCM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.75x
Industry
20.08x
Market
9.47x
ICCM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.72x
Industry
2.95x
ICCM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ICCM's financial health
Profit margin
Revenue
$911.0k
Net Income
-$4.3M
Profit Margin
-469.2%
ICCM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ICCM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.3M
Liabilities
$4.8M
Debt to equity
0.57
ICCM's short-term assets ($12.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ICCM's short-term assets ($12.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ICCM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.3M
Investing
-$51.0k
Financing
$3.5M
ICCM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ICCM vs Medical Device Stocks
Icecure Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.